Published in Exp Biol Med (Maywood) on January 01, 2013
Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy. World J Gastroenterol (2014) 0.92
TLR signaling modulates side effects of anticancer therapy in the small intestine. J Immunol (2015) 0.86
Serum-derived bovine immunoglobulin/protein isolate in the alleviation of chemotherapy-induced mucositis. Support Care Cancer (2015) 0.83
Live and heat-killed Lactobacillus rhamnosus GG upregulate gene expression of pro-inflammatory cytokines in 5-fluorouracil-pretreated Caco-2 cells. Support Care Cancer (2014) 0.83
Dietary supplementation with omega-3 fatty acid attenuates 5-fluorouracil induced mucositis in mice. Lipids Health Dis (2015) 0.79
Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis. Microb Cell Fact (2017) 0.75
The intestinal microbiome and surgical disease. Curr Probl Surg (2016) 0.75
Gut Microbial Membership Modulates CD4 T Cell Reconstitution and Function after Sepsis. J Immunol (2016) 0.75
Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol (2007) 2.24
Animal models of mucositis: implications for therapy. J Support Oncol (2011) 2.13
The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev (2007) 1.47
Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol (2007) 1.35
Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer (2012) 1.27
Swallowing dysfunction in cancer patients. Support Care Cancer (2011) 1.12
Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol (2008) 1.12
Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer (2006) 1.10
Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) (2009) 1.07
Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol (2006) 1.07
Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther (2008) 1.06
Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther (2008) 1.05
Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol (2010) 1.05
Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother Pharmacol (2008) 1.00
Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology (2005) 1.00
Gastrointestinal mucositis. Semin Oncol Nurs (2004) 1.00
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.99
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.97
A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis, p53, nuclear factor-kappaB, COX-1, and COX-2. Mol Cancer Ther (2007) 0.96
Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemother Res Pract (2012) 0.95
Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab (2009) 0.93
Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer (2013) 0.93
VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther (2007) 0.93
Chemotherapy-induced diarrhoea. Curr Opin Support Palliat Care (2009) 0.93
Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys (2005) 0.92
Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal? Cancer Chemother Pharmacol (2012) 0.91
Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol (2009) 0.91
Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med (Maywood) (2007) 0.89
Mucosal injury from targeted anti-cancer therapy. Support Care Cancer (2006) 0.88
Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Exp Biol Med (Maywood) (2010) 0.85
Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. Int J Cancer (2007) 0.85
Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis? Cancer Chemother Pharmacol (2009) 0.85
The combination of oral and small intestinal mucositis, pediatrics and biomarkers: a particularly tricky problem! Cancer Biol Ther (2006) 0.80
Irinotecan changes gene expression in the small intestine of the rat with breast cancer. Cancer Chemother Pharmacol (2006) 0.80
Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. Cancer Biol Ther (2007) 0.80
Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Invest New Drugs (2008) 0.80
Role of p53 in irinotecan-induced intestinal cell death and mucosal damage. Anticancer Drugs (2007) 0.80
The urgent need for an effective biomarker for cytotoxic therapy-induced adverse effects. Curr Opin Support Palliat Care (2013) 0.79
Severe mucositis: how can nutrition help? Curr Opin Clin Nutr Metab Care (2007) 0.79
New pharmacotherapy options for chemotherapy-induced alimentary mucositis. Expert Opin Biol Ther (2014) 0.77
Selection of housekeeping genes for gene expression studies in a rat model of irinotecan-induced mucositis. Chemotherapy (2011) 0.77
Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. Cancer Biol Ther (2012) 0.77
Biomarkers of small intestinal mucosal damage induced by chemotherapy: an emerging role for the 13C sucrose breath test. J Support Oncol (2013) 0.76
Determining the mechanisms of lapatinib-induced diarrhoea using a rat model. Cancer Chemother Pharmacol (2014) 0.76
Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the Dark Agouti rat. Int J Exp Pathol (2011) 0.76
Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Support Palliat Care (2016) 0.76
TLR4/PKC-mediated tight junction modulation: a clinical marker of chemotherapy-induced gut toxicity? Int J Cancer (2014) 0.76
Sucrose breath testing and intestinal mucositis. Cancer Biol Ther (2006) 0.75
Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract. Toxicology (2010) 0.75
Detecting gut injury during chemotherapy: is a breath test the answer? Future Oncol (2013) 0.75
Gastrointestinal mucositis: the role of MMP-tight junction interactions in tissue injury. Pathol Oncol Res (2014) 0.75
Proteasome inhibitor-induced gastrointestinal toxicity. Curr Opin Support Palliat Care (2017) 0.75
Editorial Comment: Does gut-derived inflammation enhance pain signaling following chemotherapy in a Toll-like receptor 4-dependent manner? Curr Opin Support Palliat Care (2015) 0.75